Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
暂无分享,去创建一个
Yan Sun | Luc Y Dirix | Zefei Jiang | R. Paridaens | H. Burstein | A. Tan | L. Dirix | J. Vermette | A. Awada | Zefei Jiang | R. Badwe | C. Powell | S. Jiao | Ahmad Awada | Robert Paridaens | Antoinette R Tan | Harold J Burstein | R. Abbas | Shunchang Jiao | Charles Zacharchuk | Christine Powell | Richat Abbas | Kathleen Turnbull | Anantbhushan Ranade | Gary Schwartz | Jennifer Vermette | Rajendra Badwe | C. Zacharchuk | K. Turnbull | A. Ranade | G. Schwartz | Yan Sun
[1] P. LoRusso,et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Rabindran. Antitumor activity of HER-2 inhibitors. , 2005, Cancer letters.
[3] M. Birkner,et al. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. , 2009 .
[4] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[5] J. Baselga,et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy , 2008 .
[6] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[7] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Ramaswamy Nilakantan,et al. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase , 2004, Cancer Research.
[9] K. Blackwell,et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Baselga,et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Suzanne F. Jones,et al. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors , 2009, Clinical Cancer Research.
[12] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[13] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[15] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[16] S. Franco,et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. , 2008, Annals of Oncology.
[17] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[18] S. Loibl,et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Arbushites,et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] H. Gómez,et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Hwang,et al. Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Ramaswamy Nilakantan,et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. , 2005, Journal of medicinal chemistry.